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Objective: To investigate the clinical and pathological characteristics of arsenic-related bladder cancer.
Methods: From 2008 through 2011, data on 7699 patients with bladder cancer were extracted from the
Taiwan Cancer Registry Database. A diagnosis of bladder cancer (International Statistical Classiﬁcation of
Diseases and Related Health Problems, 9th Revision: 188) was conﬁrmed in all patients. Using birth
residency codes, patients were divided into three groups: the core zone (CZ; an arsenic endemic area
with well water arsenic levels of 350e1100 ng/mL); zone 1 (Z1; an area with well water arsenic levels
of 350 ng/mL but not a blackfoot disease-endemic area); and zone 2 (Z2; an area with well water
arsenic levels of< 350 ng/mL). Clinicopathological characteristics and survival outcomes were compared
between the three groups.
Results: In this cohort, 119 (1.5%), 1145 (14.9%), and 6435 (83.6%) patients were born in the CZ, Z1, and Z2,
respectively. A higher proportion of female patients (35.3%, 31.4%, and 27.5%; p ¼ 0.014) and lower
smoking rates (29%, 34.8%, and 35.9%; p ¼ 0.694) were noted in the CZ compared with Z1 and Z2. CZ
patients had more high-grade differentiated (80.9%, 69.9%, and 63.0%; p < 0.001) and high clinical stage
(stages IIeIV, 52.8%, 38.1%, and 31.8%; p < 0.001) tumors compared with Z1 and Z2 patients. Radical
cystectomy was infrequently performed for clinical stage II (19.6%) and stage III (25.2%) bladder cancer
patients. CZ patients had signiﬁcantly shorter overall and cancer-speciﬁc survival durations compared
with Z1 and Z2 patients. Older age, female sex, higher tumor grade or stage, and higher arsenic levels
were associated with both poorer overall and cancer-speciﬁc survival in a multivariate analysis with a
Cox proportional model.
Conclusion: In Taiwan, patients with arsenic-related bladder cancer may have poorer tumor character-
istics and decreased overall and cancer-speciﬁc survival rates.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Arsenic, the 20th most abundant element in the earth's crust, is a
naturally occurring metalloid.1,2 Weathering of rocks results in
arsenic trioxide, which enters drinkingwater via dissolution in rain,
rivers, or groundwater.3 Among the sources of arsenic, contami-
nated groundwater has the highest concentration, and individuals
who rely on groundwater as a primary water supply are at risk for
inadvertent chronic arsenic exposure. West Bengal, Bangladesh,
and Taiwan (primarily the southwest coast) are the most affectedNational Taiwan University
lin Road, Douliou City, Yunlin
en).
ciation. Published by Elsevier Taiwregions worldwide for risk of arsenic exposure.4 Many epidemio-
logical studies have shown that arsenic exposure is associated with
bladder cancer, skin cancer, various internal cancers, vascular dis-
ease, diabetes mellitus, and other chronic diseases.5,6 In addition, a
doseeresponse relationship was observed between chronic arsenic
exposure from artesian well water ingestion and the incidence of
bladder cancer in several earlier, worldwide studies.7e12 Chen
et al13 had reported that individuals with high arsenic exposure (>
100 mg/L) were at a 5-fold risk of bladder cancer than those
without evident exposure.
To date, only a few studies investigating the clinicopathological
characteristics, management, and long-term clinical outcomes of
arsenic-related bladder cancer have been published. Chen et al8
revealed that arsenic-related bladder cancer patients had a
shorter overall and cancer-speciﬁc survival duration than thean LLC. Open access under CC BY-NC-ND license.
Table 1
Clinicopathological characteristics of bladder cancer patients in Taiwan.
Area Core Zone Zone 1 Zone 2 p
Cases, n 119 (1.5%) 6435 (83.6%) 119 (1.5%)
Age at diagnosis (y)
Median age 71 70 71
Range 45e87 14e96 3e99
< 40 0 18 (1.6) 112 (1.7)
40e49 3 (2.5) 73 (6.4) 405 (6.3)
50e59 17 (14.3) 225 (19.7) 1102 (17.1)
60e69 33 (27.7) 251 (21.9) 1421 (22.1)
70e79 51 (42.9) 353 (30.8) 2003 (31.1)
 80 15 (12.6) 225 (19.7) 1392 (21.6)
Sex
Men 77 (64.7) 785 (68.6) 4640 (72.1)
Women 42 (35.3) 360 (31.4) 1795 (27.9)
Men/women ratio 1.83 2.18 2.58 0.014
Smoking status
Nonsmoker 22 (1.7) 184 (13.9) 1117 (84.4) 0.69
Smoker 9 (1.2) 98 (13.4) 625 (85.4)
Hospital
Medical center 47 (39.5) 599 (52.3) 4160 (64.6)
Area hospital 72 (60.5) 546 (47.7) 2275 (35.4)
Ratio 0.65 1.10 1.83
Clinical stage <0.001
Stage 0 17 (15.7) 223 (24.9) 1410 (26.8)
Stage I 34 (31.5) 331 (37.0) 2175 (41.3)
Stage II 34 (31.5) 165 (18.5) 864 (16.4)
Stage III 12 (11.1) 83 (9.3) 389 (7.4)
Stage IV 11 (10.2) 92 (10.3) 423 (8.0)
Unclear 11 251 1174
Pathological stage <0.001
Stage 0 5 (9.1) 199 (29.3) 849 (33.4)
Stage 1 20 (36.4) 339 (49.9) 900 (35.4)
Stage 2 16 (29.1) 61 (9.0) 367 (14.4)
Stage 3 8 (14.5) 34 (5.0) 200 (7.9)
Stage 4 6 (10.9) 47 (6.9) 224 (8.8)
Unclear 64 465 3895
Differentiation <0.001
Low grade 18 (19.1) 282 (30.1) 1976 (37.0)
High grade 76 (80.9) 656 (69.9) 3361 (63.0)
Ratio (low/high) 0.24 0.43 0.59
Data are presented as n (%).
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was derived from only three hospitals and might be limited by
selection bias.
To determine the true nature of arsenic-related bladder cancers,
our study investigated the differences in clinicopathological char-
acteristics and survival outcomes in bladder cancer patients living
in areas of Taiwan with differing degrees of arsenicpollution by
analyzing a nationwide database.
2. Materials and methods
2.1. Patient population
From 2008 to 2011, 7699 patients were newly diagnosed with
bladder cancer, as bladder urothelial carcinoma, in Taiwan. Patients
with a history of bladder cancer were excluded. Datawere obtained
from the Taiwan Cancer Registry Database, which is maintained by
the Department of Health, Executive Yuan, Taiwan, and included
collected data for newly diagnosed cancer patients in every hospital
with more than a 50-bed capacity in Taiwan. Each patient had 95
columns of demographic and clinical information, including age,
sex, residency, clinical stage, pathological stage, tumor differenti-
ation, treatment, and outcomes. Tumor grade and stage were
categorized according to the World Health Organization/Interna-
tional Society of Urological Pathology System and the American
Joint Committee on Cancer/Union for International Cancer Control
system.
2.2. Deﬁnition of arsenic exposure area
Blackfoot disease, urothelial carcinoma, and some internal
cancers are endemic to several areas of Taiwan, where the arsenic
level in well water is high at 350e1100 ng/mL. We deﬁned these
areas as the core zone (CZ), including the following four towns:
Beimen and Syuejia in Tainan City and Budai and Yijhu in Chia-Yi
County. According to reports of arsenic exposure in Taiwan from
Chen et al,8 zone 1 (Z1) refers to areas surrounding the CZ, where
the arsenic level in well water is  350 ng/mL, but not considered
an endemic area for blackfoot disease. Zone 2 (Z2) refers to the
remaining areas in Taiwan, where the arsenic level in well water
is < 350 ng/mL. Patients were categorized as residing in the CZ, Z1,
or Z2 according to residency codes, which indicate the townswhere
the patients were born.
2.3. Outcome measurement
Patient information in the national cancer registry was linked to
death registry databases of the Bureau of Health Promotion,
Department of Health, Executive Yuan, Taiwan. The extracted data
included death and date of death through 2013. The median
duration of follow-up was deﬁned as the median of the interval
between the date of bladder cancer diagnosis and death or
censoring. Overall mortality and bladder cancer mortality refer to
the interval between the date of bladder cancer diagnosis and death
due to all causes or to bladder cancer, respectively.
2.4. Statistical methods
The KaplaneMeier method was used to analyze survival out-
comes. The log-rank test was used to compare survival outcomes
between the CZ, Z1, and Z2 groups. The KruskaleWallis rank test
was used to compare medians between patient groups. Contin-
gency tables were constructed for comparisons using the Chi-
square test. All statistical tests were two-tailed, and p < 0.05 wasconsidered statistically signiﬁcant. Statistical analyses were per-
formed using SPSS 21.0 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Patient demographics
From 2008 to 2011, 119 (1.5%) patients in the CZ, 1145 (14.9%)
patients in Z1, and 6435 (83.6%) in Z2 were diagnosed with bladder
urothelial carcinoma. The median age at diagnosis was 71 years in
the CZ, 70 years in Z1, and 71 years in Z2. Although median ages
among the three groups were not different, a higher proportion of
patients aged 60e79 years was seen in the CZ (70.6%) compared to
Z1 (52.8%) and Z2 (53.2%). Only 15 patients (12.6%) in the CZ were
older than 80 years, compared with 19.7% in Z1 and 21.6% in Z2.
In this nationwide cohort, the male/female ratio was 2.5. This
male predominance was generally observed throughout Taiwan,
regardless of the level of arsenic exposure. However, the male/fe-
male ratio in the CZ was signiﬁcantly lower than that in Z1 and Z2
(p ¼ 0.014). Smoking history was obtained for the last year and was
available for 2055 patients in this cohort (26.7%). A total of 732
(35.6%) patients revealed current or ever-smoking histories. Fewer
patients in the CZ had a history of smoking (29%) than in Z1 (34.8%)
or Z2 (35.9%; p ¼ 0.69). In the CZ, 60.5% of patients were diagnosed
and managed at regional hospitals, and the remaining patients
were at medical centers. In contrast, 64.5% of Z2 patients were
diagnosed and treated in medical centers (Table 1).
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Fewer patients in the CZ had clinically nonmuscle invasive
bladder cancer (stages 0 and I) compared with those in Z1 or Z2
(47.2%, 62.0%, and 68.1%, respectively; p < 0.001 for between-group
comparison). In addition, a higher level of arsenic exposure was
signiﬁcantly associated with a lower proportion of nonmuscle
invasive bladder cancer (p < 0.001 for trend). Locally advanced
(stages II and III) bladder cancer tumors were more frequently
observed among patients from the CZ compared with patients from
Z1 or Z2 (42.6%, 27.7%, and 23.8%, respectively; p < 0.001 for
between-group comparison). Similar presentations in pathological
stages were noted among the three groups (CZ, 43.6%; Z1, 14%; and
Z2, 22.3%, p < 0.001 for between-group comparison). The propor-
tion of high-grade differentiated tumors was higher in the CZ group
than in the Z1 and Z2 groups (80.9%, 69.9%, and 63.0%, respectively;
p < 0.001 for between-group comparison). In addition, Z1 patients
had more high-grade differentiated tumors than Z2 patients
(p < 0.001).
3.3. Management
For nonmuscle invasive bladder cancer, transurethral resection
was done in almost all patients (96.8% with stage 0 and 93.5% with
stage I), and there was no signiﬁcant difference in treatment be-
tween the groups (Table 2)–>. Radical cystectomy was infrequently
performed in patients with clinical stage II (19.6%) and stage III
(25.2%) disease. More CZ patients with clinical stage II and III
bladder cancer underwent radical cystectomy than in Z1 or Z2
groups, although statistical signiﬁcance was not reached (clinical
stage II, p ¼ 0.316 for between-group comparison; clinical stage III,Table 2
Management of bladder cancer patients in Taiwan.
Area Core zone Zone 1 Zone 2
Cases, n 119 (1.5) 1145 (14.9) 6435 (83.6)
Stage I
TURBT 33 (97.1) 316 (95.5) 2026 (93.1)
No treatment 0 4 (1.2) 48 (2.2)
Partial cystectomy 0 0 18 (0.8)
Radical cystectomy 1 (2.9) 10 (3.0) 63 (2.9)
Radiation 0 1 (0.3) 11 (0.5)
Simple cystectomy 0 0 6 (0.3)
Unclear surgery 0 0 3 (0.1)
Stage II
TURBT 16 (47.1) 95 (57.6) 493 (57.1)
No treatment 1 (2.9) 1 (0.6) 29 (3.4)
Partial cystectomy 1 (2.9) 8 (4.8) 36 (4.2)
Radical cystectomy 11 (32.4) 30 (18.2) 167 (19.3)
Radiation 3 (8.8) 30 (18.2) 132 (15.3)
Simple cystectomy 2 (5.9) 1 (0.6) 6 (0.7)
Unclear surgery 0 0 1 (0.1)
Stage III
TURBT 1 (8.3) 33 (39.8) 159 (40.9)
No treatment 0 2 (2.4) 15 (3.9)
Partial cystectomy 2 (16.7) 8 (9.6) 16 (4.1)
Radical cystectomy 5 (41.7) 20 (24.1) 97 (24.9)
Radiation 4 (33.3) 20 (24.1) 100 (25.7)
Simple cystectomy 0 0 2 (0.5)
Stage IV
Systemic chemotherapy 7 (63.6) 43 (46.7) 184 (43.5)
TURBT 2 (18.2) 19 (20.7) 140 (33.1)
No treatment 1 (9.1) 9 (9.8) 48 (11.3)
Partial cystectomy 0 1 (1.1) 3 (0.7)
Radical cystectomy 1 (9.1) 20 (21.7) 45 (10.6)
Simple cystectomy 0 0 1 (0.2)
Unclear surgery 0 0 2 (0.5)
Data are presented as n (%).
TURBT ¼ transurethral resection of bladder tumors.p ¼ 0.658 for between-group comparison). Radiation to the urinary
bladder was used for 289 (18.7%) patients with clinical stage II and
stage III bladder cancer. For clinical stage III bladder cancer, more
patients in the CZ group received radiotherapy than in the Z1 and
Z2 groups, but the difference did not reach statistical signiﬁcance
(p ¼ 0.408). CZ patients with clinical stage IV disease received
systemic chemotherapy more frequently than did those in Z1 and
Z2, but again statistical signiﬁcance was not achieved (p ¼ 0.708).
3.4. Survival outcomes
A total of 2070 (26.9%) patients in our cohort died during a
median follow-up of 26.9 months. More CZ patients (38.7%) died
than did patients in Z1 (28.1%, p ¼ 0.214) and Z2 (26.4%, p ¼ 0.004).
CZ patients had a signiﬁcantly shorter overall survival duration
compared with patients in Z1 and Z2 (log-rank test, p ¼ 0.008 and
p ¼ 0.001, respectively; Fig. 1A). In our cohort, 1118 (14.5%) patients
died from bladder cancer by the end of 2013. More patients (26.9%)
in the CZ died from bladder cancer than did patients in Z1 (15.3%,
p ¼ 0.002) or Z2 (14.2%, p < 0.001). CZ patients had signiﬁcantly
worse cancer-speciﬁc survival outcomes compared with Z1 and Z2
patients (log-rank test, p < 0.001 and p < 0.001, respectively; Fig. 2).
However, there were no differences in overall survival or in cancer-
speciﬁc survival between Z1 and Z2 patients.
Based on the Cox proportional hazardmodel for overall survival,
old age, female sex, high tumor grade and stage, and high arsenic
levels were associated with a reduced overall survival duration
(Table 3). Althoughmore CZ patients received treatment in regional
hospitals than Z1 and Z2 patients, there were no signiﬁcant dif-
ferences in overall survival outcomes between regional hospitals
and medical centers. A multivariable analysis for overall survival
revealed that Z1 and Z2 patients had borderline beneﬁts (p ¼ 0.047Fig. 1. Overall survival of bladder cancer patients stratiﬁed by levels of arsenic
contamination. Core zone (CZ; arsenic endemic area with a well water arsenic level of
350e1100 ng/mL), zone 1 (Z1; a well water arsenic level of 350 ng/mL but not a
blackfoot disease endemic area), and zone 2 (Z2; a well water arsenic level of < 350 ng/
mL).
Fig. 2. Cancer-speciﬁc survival of bladder cancer patients stratiﬁed by the levels of
arsenic contamination. Core zone (CZ; arsenic endemic area with a well water arsenic
level of 350e1100 ng/mL), zone 1 (Z1; a well water arsenic level of 350 ng/mL but
not a blackfoot disease endemic area), and zone 2 (Z2; a well water arsenic level
of< 350 ng/mL).
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tumor grade and stage, and arsenic levels remained prognostic for
cancer-speciﬁc survival; in the multivariable analysis, CZ patients
had poorer survival outcomes than the others.4. Discussion
In our study, patients with bladder cancer in the CZ were pri-
marily between the ages of 60 years and 79 years; had a higher
proportion of females; had higher tumor grade differentiation; and
higher clinical and pathological stages than did the patients in the
other areas of Taiwan. Chen et al8 had noted that more unfavorable
bladder cancer stage distribution and survival outcomes were seen
in patients with a higher level of arsenic exposure in a limited
cohort. Our study, using a nationwide database of bladder cancer
patients, between 2008 and 2011, found similar results. For both
overall survival and cancer-speciﬁc survival, CZ patients had poorer
outcomes compared with patients in Z1 and Z2, where the arsenic
levels in well water were lower. Other than arsenic exposure,
possible reasons that patients in the CZ tended to have higher stage
and grade bladder cancer and poorer clinical outcomes may have
included: (1) fewer patients were treated inmedical centers and (2)
the higher proportion of elderly patients in the CZ group.
Cigarette smoking is a well-documented cause of bladder can-
cer, with about 50% of all bladder cancers attributable to smoking.14
In our study, patients in the CZ had less smoking history compared
with those patients in Z1 and Z2. However, more advanced stage
and higher grade of bladder cancers were noted in CZ patients than
in Z1 and Z2 patients. Chen et al8 had reported that smoking was
not an independent prognostic factor for survival in patients with
arsenic-related bladder cancer. In fact, the carcinogenic effects of
cigarette smoking seem to be weaker than those of arsenic,7 andour results support this ﬁnding. Furthermore, a synergistic rela-
tionship may exist between arsenic and smoking in regard to
bladder cancer. Ferreccio et al15 had identiﬁed doseeresponse
patterns for arsenic in smokers and nonsmokers living in areas of
high arsenic concentrations. Further studies should be conducted
to evaluate the effects of nicotine dose and bladder cancer tumor
grade in arsenic-exposed populations.
As for treatment options, more clinical stage II patients in the CZ
underwent radical cystectomy and more clinical stage IV patients
received systemic chemotherapy compared with those in other
areas. This indicates that a proportionally higher number of in-
dividuals in the CZ received standard therapy than individuals in
other areas. This may be related to the awareness of cancer risk in
arsenic endemic areas, and that patients were willing to receive
standard treatment for bladder cancer. Taiwan's government has
paid much attention to health issues in areas with blackfoot dis-
ease, and epidemiological cohort studies have provided free
screening programs for residents in arsenic endemic areas for many
years.7,16 This may explain why residents in the CZ had a higher
awareness of health risks and were willing to acceptmedical advice
as compared with residents of other areas.
A high incidence of upper urinary tract urothelial carcinoma
(UTUC) in arsenic-endemic areas in southwestern Taiwan has been
documented,17,18 and the characteristics of UTUC in the endemic
areas of Blackfoot disease include: (1) male/female ratio of 1:2; (2) a
younger age of onset (55e60 years); and (3) ureteral tumors twice
as common as the renal pelvis site.18 The male/female ratio in UTUC
is contrary to the bladder urothelial carcinoma results in our study.
In addition to bladder urothelial carcinoma, arsenic exposure
combined with cigarette smoking contributes to a higher risk of
UTUC.17 However, this previous study was limited by a hospital-
based, caseecontrol design. It is necessary to conduct a nation-
wide study investigating the relationship between arsenic expo-
sure, cigarette smoking, Chinese herb use, and urothelical
carcinoma, and further understand the susceptibility of different
sites of urothelium to potential environmental carcinogens.
4.1. Limitations
Our study has several limitations. First, we used a census reg-
ister for stratifying patients into three zones; however, the census
register does not always reﬂect the actual place of residency.
Therefore, the exact number of patients in each zone may not be
clearly identiﬁed. Second, despite the fact that we had treatment
guidelines for bladder cancer in place, the efforts made by indi-
vidual physicians to persuade patients to undergo surveillance or
radical surgery may have differed. Moreover, the database did not
reveal the use of post-transurethral bladder tumor resection
instillation therapy, and it did not collect data on the number of
patients with clinical stage II or stage III disease who received
systemic chemotherapy either. The survival outcomes might
therefore be biased accordingly. Third, only 119 CZ patients were
enrolled, which is relatively smaller than the number of patients
enrolled from Z1 or Z2. This may have masked minor differences in
clinical outcomes. Fourth, our study was a retrospective study, in
which data accuracy may be inferior to that of a prospective study.
Fifth, the study period was relatively short. Extending the study
period in future trials will help make the ﬁndings more robust.
5. Conclusion
Bladder cancer patients who live in a high arsenic endemic area
(the CZ) had higher clinical and pathological stage cancers and had
poorer overall and cancer-speciﬁc survival rates than patients living
in other areas of Taiwan.
Table 3
Univariate and multivariate analyses of overall and cancer-speciﬁc deaths in bladder cancer patients.
Factors Cases, n Overall death
Deaths, n Univariate Multivariate
HR CI p HR CI p
Age 7699 2070 1.05 1.05e1.06 < 0.001 1.05 1.05e1.06 < 0.001
Arsenic levels
Core zone 119 46 Ref. Ref.
Zone 1 1145 322 0.66 0.49e0.91 0.01 0.73 0.54e1.00 0.047
Zone 2 6435 1702 0.62 0.46e0.83 0.001 0.75 0.56e1.00 0.051
Sex
Male 5502 1422 Ref. Ref.
Female 2197 648 1.1 1.05e1.15 < 0.001 1.08 1.03e1.13 0.001
Hospital levels
Regional 2893 760 Ref. Ref.
Medical center 4806 1310 1 0.95e1.05 0.948 1.03 0.98e1.07 0.283
Grade
Low 2276 328 Ref. Ref.
High 4093 1300 1.39 1.31e1.48 < 0.001 1.2 1.13e1.28 < 0.001
Stage
0 1650 208 Ref. Ref.
I 2540 454 1.41 1.19e1.66 < 0.001 1.21 1.02e1.43 0.026
II 1063 363 3.05 2.57e3.62 < 0.001 2.32 1.95e2.77 < 0.001
III 484 233 4.8 3.98e5.79 < 0.001 3.6 2.97e4.36 < 0.001
IV 526 423 12.9 10.9e15.2 < 0.001 9.89 8.31e11.72 < 0.001
Factors Cases, n Cancer-speciﬁc death
Cancer-speciﬁc
deaths, n
Univariate Multivariate
HR CI p HR CI p
Age 7699 1118 1.05 1.04e1.05 < 0.001 1.04 1.04e1.05 < 0.001
Arsenic levels
Core zone 119 32 Ref. Ref.
Zone 1 1145 175 0.53 0.36e0.77 0.001 0.6 0.41e0.88 0.008
Zone 2 6435 911 0.48 0.34e0.69 < 0.001 0.64 0.45e0.92 0.015
Sex
Male 5502 751 Ref. Ref.
Female 2197 367 1.13 1.06e1.21 < 0.001 1.1 1.04e1.17 0.002
Hospital levels
Regional 2893 399 Ref. Ref.
Medical center 4806 719 1.03 0.97e1.09 0.406 1.06 1.00e1.13 0.061
Grade
Low 2276 105 Ref. Ref.
High 4093 760 1.69 1.55e1.85 < 0.001 1.39 1.26e1.52 < 0.001
Stage
0 1650 62 Ref. Ref.
I 2540 170 1.78 1.33e2.37 < 0.001 1.43 1.07e1.92 0.017
II 1063 214 6 4.53e7.97 < 0.001 4.15 3.11e5.54 < 0.001
III 484 156 10.69 7.96e14.35 < 0.001 7.17 5.31e9.68 < 0.001
IV 526 319 31.87 24.26e41.88 < 0.001 21.94 16.60e28.99 < 0.001
CI ¼ conﬁdence interval; cStage ¼ clinical stage; HR ¼ hazard ratio.
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